0001209191-21-038751.txt : 20210607 0001209191-21-038751.hdr.sgml : 20210607 20210607184019 ACCESSION NUMBER: 0001209191-21-038751 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210603 FILED AS OF DATE: 20210607 DATE AS OF CHANGE: 20210607 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Foley Todd CENTRAL INDEX KEY: 0001473930 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39335 FILM NUMBER: 211000789 MAIL ADDRESS: STREET 1: THE JOHN HANCOCK TOWER STREET 2: 200 CLARENDON STREET 54TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Repare Therapeutics Inc. CENTRAL INDEX KEY: 0001808158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7210 FREDERICK-BANTING, SUITE 100 CITY: ST-LAURENT STATE: A8 ZIP: H4S 2A1 BUSINESS PHONE: (857) 412-7018 MAIL ADDRESS: STREET 1: 7210 FREDERICK-BANTING, SUITE 100 CITY: ST-LAURENT STATE: A8 ZIP: H4S 2A1 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-06-03 0 0001808158 Repare Therapeutics Inc. RPTX 0001473930 Foley Todd C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 1 0 0 0 Common Shares 2021-06-03 4 S 0 9824 31.92 D 2373848 I See Footnote Common Shares 2021-06-04 4 S 0 3544 30.80 D 2370304 I See Footnote Common Shares 2021-06-04 4 S 0 2068 31.28 D 2368236 I See Footnote Common Shares 2021-06-07 4 S 0 1058 30.74 D 2367178 I See Footnote Common Shares 2021-06-07 4 S 0 749 32.25 D 2366429 I See Footnote Common Shares 2021-06-07 4 S 0 8379 32.96 D 2358050 I See Footnote Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. The shares were sold as follows: 9,497 by MPM BioVentures 2014, L.P. ("BV 2014") and 327 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.35 to $32.265 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held as follows: 2,163,535 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)") and 74,470 by AM BV2014. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Todd Foley is a managing director of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. The shares were sold as follows: 3,426 by BV 2014 and 118 by AM BV2014. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.10 to $31.09 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held as follows: 2,160,109 by BV 2014, 135,843 by BV 2014(B) and 74,352 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. The shares were sold as follows: 1,999 by BV 2014 and 69 by AM BV2014. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.10 to $31.54 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held as follows: 2,158,110 by BV 2014, 135,843 by BV 2014(B) and 74,283 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. The shares were sold as follows: 1,023 by BV 2014 and 35 by AM BV2014. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.41 to $31.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held as follows: 2,157,087 by BV 2014, 135,843 by BV 2014(B) and 74,248 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. The shares were sold as follows: 724 by BV 2014 and 25 by AM BV2014. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.50 to $32.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held as follows: 2,156,363 by BV 2014, 135,843 by BV 2014(B) and 74,223 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. The shares were sold as follows: 8,100 by BV 2014 and 279 by AM BV2014. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.50 to $33.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held as follows: 2,148,263 by BV 2014, 135,843 by BV 2014(B) and 73,944 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. /s/ Todd Foley 2021-06-07